Loading…
NovaBridge Biosciences is projected to rise to $1.99 by 2027, a +6% move from its current price of $1.87. NBP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.81 | $1.87 | $1.93 | +0.04% |
| May 30 | $1.79 | $1.87 | $1.95 | +0.09% |
| May 31 | $1.78 | $1.87 | $1.97 | +0.13% |
| Jun 1 | $1.76 | $1.87 | $1.99 | +0.17% |
| Jun 2 | $1.75 | $1.87 | $2.01 | +0.22% |
| Jun 3 | $1.74 | $1.87 | $2.02 | +0.26% |
| Jun 4 | $1.73 | $1.88 | $2.03 | +0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.73 | $1.88 | $2.03 | +0.30% |
| Week 2 | $1.68 | $1.88 | $2.11 | +0.61% |
| Week 3 | $1.64 | $1.89 | $2.17 | +0.92% |
| Week 4 | $1.61 | $1.89 | $2.22 | +1.22% |
| Week 5 | $1.59 | $1.90 | $2.27 | +1.53% |
| Week 6 | $1.56 | $1.90 | $2.32 | +1.84% |
| Week 7 | $1.54 | $1.91 | $2.36 | +2.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NovaBridge Biosciences is a biotechnology company that engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1 clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab.
The company was formerly known as I-Mab and changed its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
NovaBridge Biosciences (NBP) is a biotechnology stock with a current price of $1.77, a market cap of $204.7M, and a rank of 3831. The stock sits in the small-cap space with a diversified pipeline across oncology and ophthalmology programs. The price outlook described in the forecast shows neutral near-term momentum and bullish longer-term potential, reflecting evolving clinical progress and partnerships.
In the near term the forecast suggests modest activity with some downside and upside along the way, while the long-term outlook points to meaningful upside driven by ongoing and planned developments in its immuno-oncology and ocular programs. These figures are estimates and not guarantees, and actual results may differ.
A major floor 43.1% below — a decisive break under it would weaken the trend.
The nearest floor, 10.2% below — buyers have tended to step in here.
The nearest ceiling, 44.4% above — a clean break opens room to run.
A major ceiling 112.8% above — clearing it would confirm fresh momentum.
Key NBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.81 | Buy | $1.83 | Buy |
| MA 10 | $1.82 | Buy | $1.87 | Sell |
| MA 20 | $2.05 | Sell | $2.01 | Sell |
| MA 50 | $2.34 | Sell | $2.36 | Sell |
| MA 100 | $2.93 | Sell | $2.77 | Sell |
| MA 200 | $3.64 | Sell | $2.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.82 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -52.72 | Neutral |
| Williams %R (14) | -64.81 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -15.00 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 35.19 | Neutral |
| TRIX (15) | -1.14 | Sell |
| Awesome (5,34) | -0.44 | Sell |
| Ultimate (7,14,28) | 43.46 | Neutral |
| Momentum (10) | -0.19 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 1.84 | Buy |
| ADX (14) | 36.00 | Sell |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 30. The stock trades below its near-term average pressures, as shown by SMA50 at $2.38 and SMA200 at $3.65. Support is identified at $1.68 and resistance at $2.70, indicating a cautious range ahead.
The 30-day price range runs from $1.45 to $2.16, highlighting limited upside within the month. Overall, near-term momentum remains flat to modest, and the volatility remains elevated at 60% annualized.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.68 | $1.87 | $2.51 | 0% | Neutral | |
| $1.56 | $1.99 | $2.70 | +6% | Neutral | |
| $1.41 | $1.86 | $2.62 | -1% | Neutral | |
| $1.47 | $1.99 | $2.89 | +6% | Neutral | |
| $1.45 | $2.00 | $2.99 | +7% | Neutral | |
| $1.51 | $2.13 | $3.25 | +14% | Neutral | |
| $1.81 | $2.61 | $4.06 | +39% | Bullish | |
| $1.89 | $2.77 | $4.40 | +48% | Bullish | |
| $1.86 | $2.77 | $4.48 | +48% | Bullish | |
| $1.79 | $2.71 | $4.44 | +45% | Bullish | |
| $2.45 | $4.01 | $7.03 | +114% | Bullish | |
| $3.19 | $5.98 | $11.54 | +220% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.68 | $1.87 | $2.21 | +0.00% |
| June 2026 | $1.66 | $1.95 | $2.35 | +4.24% |
| July 2026 | $1.64 | $1.95 | $2.38 | -0.19% |
| August 2026 | $1.62 | $1.94 | $2.41 | -0.05% |
| September 2026 | $1.68 | $2.02 | $2.52 | +3.77% |
| October 2026 | $1.69 | $2.04 | $2.58 | +1.33% |
| November 2026 | $1.63 | $1.98 | $2.52 | -3.12% |
| December 2026 | $1.60 | $1.96 | $2.51 | -1.16% |
Click any year to see its month-by-month NBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NBP is projected to trade between $1.68 and $2.51, averaging $1.87 — a potential gain of 0% from today's $1.87. A consolidation phase looks the most probable path here.
NovaBridge Biosciences's 2027 outlook centres on $1.99, within a $1.56 to $2.70 range. That is up +6% on the projected 2026 average. That marks a +6% change versus current levels. Price action looks broadly range-bound.
By 2028, NBP could reach as high as $2.62, with a base case around $1.86 and support toward $1.41 — roughly -1% from $1.87. A consolidation phase looks the most probable path here.
Expect NBP to range from $1.47 to $2.89 through 2029. The $1.99 average target implies a +6% move from current prices. That is up +7% on the projected 2028 average. Price action looks broadly range-bound.
The NBP price prediction for 2030 points to an average of $2.00 (low $1.45, high $2.99) — a potential gain of +7% on today's $1.87. A consolidation phase looks the most probable path here.
In 2031, NBP is projected to trade between $1.51 and $3.25, averaging $2.13 — a potential gain of +14% from today's $1.87. That is up +6% on the projected 2030 average. Price action looks broadly range-bound.
NovaBridge Biosciences's 2032 outlook centres on $2.61, within a $1.81 to $4.06 range. That is up +22% on the projected 2031 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, NBP could reach as high as $4.40, with a base case around $2.77 and support toward $1.89 — roughly +48% from $1.87. Momentum favours further upside here.
Expect NBP to range from $1.86 to $4.48 through 2034. The $2.77 average target implies a +48% move from current prices. That is up 0% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The NBP price prediction for 2035 points to an average of $2.71 (low $1.79, high $4.44) — a potential gain of +45% on today's $1.87. Momentum favours further upside here.
In 2040, NBP is projected to trade between $2.45 and $7.03, averaging $4.01 — a potential gain of +114% from today's $1.87. That is up +48% on the projected 2035 average. Buyers look set to stay in control over this stretch.
NovaBridge Biosciences's 2050 outlook centres on $5.98, within a $3.19 to $11.54 range. That is up +49% on the projected 2040 average. That marks a +220% change versus current levels. Momentum favours further upside here.
Investing $1,000 in NBP today (≈ 534.759358 NBP) could be worth
$3,200.28
+$2,200.28 (+220%) by 2050 · US Dollar
Based on the average projected NBP price of $5.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NBPwould be worth at today's price.
$1,000 invested in NBP on May 27, 2025 (≈ 961.538497 NBP) would be worth
$1,798.08
+$798.08 (+79.8%) today · 1.80× · US Dollar
Based on a NBP entry price of $1.04 vs. today's $1.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.76 | $1,062.5 | +6.3% |
| 1 month ago | $2.43 | $769.55 | -23.0% |
| 3 months ago | $3.28 | $570.12 | -43.0% |
| 6 months ago | $3.84 | $486.98 | -51.3% |
| 1 year ago | $1.04 | $1,798.08 | +79.8% |
| All time (5.0y) ago | $80 | $23.38 | -97.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NBP forecast.
Our base-case forecast reaches $3.70 around 2040.
Implied market cap at $3.70: $427.9M
The multi-year forecast shows a path from near-term neutrality toward longer-term bullish momentum as the pipeline advances and partnerships mature. The 2026 forecast sits at min $1.68, avg $1.77, max $2.38 with ROI 0 and NEUTRAL sentiment. In 2027, min $1.47, avg $1.88, max $2.55 with ROI 6 and NEUTRAL sentiment.
2028 slides to min $1.32, avg $1.74, max $2.45 with ROI -1.8 and NEUTRAL sentiment, followed by 2029 at min $1.39, avg $1.87, max $2.72 with ROI 5.7 and NEUTRAL sentiment. For 2030, min $1.35, avg $1.86, max $2.78 with ROI 5.3 and NEUTRAL sentiment, and 2031 at min $1.38, avg $1.95, max $2.98 with ROI 10.3 and NEUTRAL sentiment.
The forecast turns bullish in 2032 (min $1.69, avg $2.43, max $3.79; ROI 37.2) and remains bullish through 2033 (min $1.75, avg $2.57, max $4.08; ROI 45), 2034 (min $1.71, avg $2.55, max $4.12; ROI 43.8), and 2035 (min $1.66, avg $2.51, max $4.13; ROI 42).
By 2040 the forecast shows a strong bullish case with min $2.24, avg $3.67, max $6.44 and ROI 107.3. The journey culminates in 2050 with min $2.91, avg $5.46, max $10.55 and ROI 208.7, both clearly bullish. These are estimates, not guarantees, and depend on clinical progress, regulatory outcomes, and market factors.
Tap a question to reveal the answer.
Avg price $1.86; min $1.35; max $2.78; ROI 5.3; sentiment NEUTRAL.
Yes: 2040 forecast shows min $2.24, avg $3.67, max $6.44; ROI 107.3; sentiment BULLISH.
2032 min $1.69, avg $2.43, max $3.79, ROI 37.2; 2033 min $1.75, avg $2.57, max $4.08, ROI 45; 2034 min $1.71, avg $2.55, max $4.12, ROI 43.8; 2035 min $1.66, avg $2.51, max $4.13, ROI 42.
Current price $1.77; market cap $204.7M; rank 3831.
RSI14 30, sentiment NEUTRAL. SMA50 $2.38, SMA200 $3.65. Support $1.68, resistance $2.70. 30-day range $1.45–$2.16.
NovaBridge Biosciences Community Discussion
0Share your NovaBridge Biosciences price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.